{"id":"NCT03447249","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","officialTitle":"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-07","primaryCompletion":"2019-02-05","completion":"2019-02-05","firstPosted":"2018-02-27","resultsPosted":"2020-03-13","lastUpdate":"2020-03-13"},"enrollment":385,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"VX-659/TEZ/IVA","otherNames":["VX-659/VX-661/VX-770","VX-659/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"VX-659/TEZ/IVA TC","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects).","primaryOutcome":{"measure":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","timeFrame":"From Baseline at Week 4","effectByArm":[{"arm":"Placebo","deltaMin":-1,"sd":0.6},{"arm":"VX-659/TEZ/IVA TC","deltaMin":13,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":101,"countries":["United States","Australia","Canada","Denmark","Germany","Ireland","Israel","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":189},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Sputum increased","Headache","Upper respiratory tract infection"]}}